Breaking News
Get 45% Off 0
🚨 Don’t miss your updated list of AI-picked stocks for this month
Pick Stocks with AI

Acorda Resubmits NDA For Parkinson's Disease Candidate Inbrija

By Zacks Investment ResearchStock MarketsDec 08, 2017 03:41AM ET
www.investing.com/analysis/acorda-resubmits-nda-for-parkinsons-disease-candidate-inbrija-200271726
Acorda Resubmits NDA For Parkinson's Disease Candidate Inbrija
By Zacks Investment Research   |  Dec 08, 2017 03:41AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
AMZN
-2.62%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AZN
-0.25%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ACORQ
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AZN
+0.17%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PRTA
+3.99%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ADMS
+0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Acorda Therapeutics (NASDAQ:ACOR) announced that it has resubmitted the new drug application (NDA) for its late stage pipeline candidate, Inbrija, to the FDA. Following the news, shares of the company gained by about 1.9%. So far this year, shares of the company have increased 10.4% compared with the industry’s gain of 0.7%.

Currently, the company is seeking approval for Inbrija in the United States as a treatment option for symptoms of OFF periods in people with Parkinson’s taking a carbidopa / levodopa regimen.

We remind investors that in August the company received a refusal to file (RTF) letter from the FDA in connection with the new drug application (NDA) that it first submitted in June. However, the FDA declared the application to be incomplete after a preliminary review. As a result, the regulatory body required additional supporting information to review the application.

Notably, the FDA stated two main reasons for the RTF — date specification as to when the manufacturing site can be ready for inspection and questions related to drug master production record. Additionally, the FDA asked for some extra data, unrelated to the main issues of the RTF. Acorda claims that it has addressed these two issues in its resubmission.

Acorda had submitted the NDA as a 505(b)(2) application. The FDA is expected to inform the company within 74 days if the submission is complete and requires a full review.

In this context, we remind investors that in November, Acorda decided to immediately discontinue the phase III study on one of its lead Parkinson’s disease candidates, tozadenant. The decision was based on some serious safety issues observed in the study.

Apart from Acorda, many companies are trying to introduce treatments for Parkinson’s disease in the market namely, Prothena Corporation’s (NASDAQ:PRTA) PRX002, AstraZeneca’s (NYSE:AZN) MEDI1341, Prexton Therapeutics’ Foliglurax and Prana Biotechnology’s PBT434.

Also, Adamas Pharmaceuticals’ (NASDAQ:ADMS) Gocovri received an FDA approval in August for treating dyskinesia in patients with Parkinson’s disease.

Zacks Rank

Acorda carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>



Astrazeneca PLC (LON:AZN): Free Stock Analysis Report

Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report

Prothena Corporation PLC (PRTA): Free Stock Analysis Report

Adamas Pharmaceuticals, Inc. (ADMS): Free Stock Analysis Report

Original post

Zacks Investment Research

Acorda Resubmits NDA For Parkinson's Disease Candidate Inbrija
 

Related Articles

Acorda Resubmits NDA For Parkinson's Disease Candidate Inbrija

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email